Impulsive Aggression Comorbid With ADHD
2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Supernus PharmaceuticalsMD - Rockville
2 programs1
1
SPN-810Phase 21 trial
SPN-810MPhase 11 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Supernus PharmaceuticalsSPN-810
Supernus PharmaceuticalsSPN-810M
Clinical Trials (2)
Total enrollment: 128 patients across 2 trials
A Study to Evaluate the Efficacy and Safety of SPN-810 as Adjunctive Therapy in Children With Impulsive Aggression Comorbid With Attention-Deficit/Hyperactivity Disorder (ADHD)
Start: Jun 2011Est. completion: Oct 2012121 patients
Phase 2Completed
Phase I Study to Assess the Absorption, Metabolism, and Excretion of [14C] Labeled SPN-810M
Start: Nov 2013Est. completion: Dec 20137 patients
Phase 1Completed
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.